Binoclar 500mg 7pcs

Clarithromycin is indicated in:

• Lower respiratory tract infection: acute and chronic bronchitis and pneumonia;
• Upper respiratory tract infection: sinusitis and pharyngitis, Community-acquired pneumonia, atypical pneumonia;
• Skin and soft tissue infection;
• Adjunct in the treatment of duodenal ulcers to eradicate of H. pylori

Clarithromycin acts by inhibiting microsomal protein synthesis in susceptible organisms mainly by binding to the donor site on the 50S sub- unit of the bacterial ribosome and preventing translocation to that site.

Clarithromycin is active against most Gram-positive bacteria and Chlamydia, some Gram-negative bacteria and Mycoplasmas.

Clarithromycin’s activity is the same as, or greater than, that of erythromycin in vitro against most Gram-positive bacteria. Clarithromycin is more acid stable than erythromycin and therefore, is better tolerated. Clarithromycin has twice the activity of erythromycin against H. influenzae. Most species of Gram-negative bacteria are resistant to clarithromycin because of failure to penetrate to the target.

Adults:

• Pharyngitis/Tonsillitis: 250 mg for 10 days
• Acute maxillary sinusitis: 500 mg for 14 days
• Chronic bronchitis: 250 – 500 mg for 7-14 days
• Pneumonia: 250 mg for 7-14 days
• Uncomplicated skin and skin structure infections: 250 mg for 7-14 days
• Community-acquired upper and lower respiratory tract infections: 250 – 500 mg for 5-14 days

This may be given with or without meals.

Contraindications

Hypersensitive to Clarithromycin, Erythromycin or any of the macrolide antibiotics. Patients receiving terfenadine who have pre-existing cardiac abnormalities or electrolyte disturbances.

Clarithromycin is not recommended for pregnant women. Breast milk from mothers receiving Clarithromycin should not be given to infants until treatment is completed.